Free trade agreements struck across the globe are blocking hundreds of millions of dollars in savings from generic and biosimilar competition via restrictive intellectual property and exclusivity provisions, according to an IQVIA study hosted by the International Generic and Biosimilar medicines Association.
In the study on the impact of FTAs, IQVIA reviews the effect of “originator-favoring government incentives on the success of generic and biosimilar medicines markets”, focusing specifically on “FTAs and associated provisions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?